Latest Cash Reserves News

Sports Entertainment Group (ASX:SEG) posted a 39% revenue jump and 73% underlying EBITDA growth in FY26, offset by a 93% net profit decline due to tax and one-off impacts. The company is poised for growth with key acquisitions including MediaWorks NZ and the GIANTS Netball license.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Ora Banda Mining delivered record FY26 results with a 53% jump in gold production and doubled revenue to $807.5 million, underpinning its DRIVE to 300 growth strategy targeting 300,000 ounces annually by FY29.

Hearts and Minds Investments Limited (HM1) saw its profit after tax drop 57% to $46.4 million for FY26, amid a portfolio return slowdown to 5.2%. The company declared a 10-cent fully franked final dividend and maintained its $11.4 million commitment to Australian medical research.

DroneShield Limited reported record revenue of $125.8 million for the half-year ended June 2026, driven by recurring income and geographic diversification, while posting a $32.2 million statutory loss due to margin pressure and strategic investments.

Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

FOS Capital reported a 12% revenue decline and an EBITDA loss of $0.5 million in FY26, impacted by softer market conditions and project delays. However, a $10 million order book and record $130 million pipeline set the stage for a potential turnaround in FY27.

Sinclair Gold has cleared a key drilling milestone at its Mt Henry project, prompting a $5 million cash payment to Westgold and cancelling over 7.5 million performance rights. The company also moves closer to completing a royalty deal with Stria Lithium, while preparing for a resource update by year-end.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.